We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Reasons for Rejecting Blood Samples Analyzed

By LabMedica International staff writers
Posted on 24 Jan 2012
A determination has been made of what types of preanalytical errors that leads to rejection of blood samples in the clinical laboratory. More...


Errors in clinical laboratories have a great impact on safety and care of patients, and need to be carefully analyzed for improvements to be made in the preanalytical phase, which is responsible for about 70% of errors.

Laboratory scientists at the University Hospital (Porto Alegre, Brazil) carried out an analysis of rejected samples and consequent request for new daily collections of blood for conduction of tests in the following analytical departments: biochemical-immunoassay and hematology. The analysis was performed on data collected from June to August 2010.

The rejection criteria in clotted, hemolyzed, icteric and lipemic samples were visually applied by two technologists and the criterion for the clotted sample was only analyzed in samples collected in ethylenediamine tetra-acetic acid (EDTA) or sodium citrate tubes. The rejection criterion for icteric samples was applied in samples with seric bilirubin levels greater than 25 mg/L that could interfere with the measurement of some tests, such as those for albumin, cholesterol, and total protein. Lipemic samples, in turn, were rejected when serum triglycerides levels exceeded 400 mg/dL, as that may inhibit the tests for amylase, uric acid, urea, bilirubin and total protein.

Of the 77,051 blood samples that were collected during the three months period, 441 (0.57%) were rejected by some type of preanalytical error and therefore had to be recollected. A clot was found in 43.8% of disallowed samples and was found to be the major cause of rejection of samples, followed by 24% with insufficient sample volume. The third most frequent cause for rejecting samples were hemolyzed samples, which involved 17.9% of cases. Other reasons for rejection of samples were misidentification, inappropriate tube, lipemic samples, inadequate sample/additive ratio, and insignificant icteric samples.

The authors concluded that in their laboratory, despite the percentage of preanalytical errors being small, the appearance of laboratory errors could be provoke an adverse impact on patient care. For example, when blood constituents such as potassium, magnesium, iron, lactate dehydrogenase, phosphorus, ammonium, and total protein are falsely increased during hemolysis. In this context, the poor quality specimens could influence laboratory results, which would be clinically incorrect and therefore mislead the physician whose intervention might be unsuccessful. The study was published in January 2012 in the journal Clinical Biochemistry.

Related Links:

University Hospital Porto Alegre



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.